The DOI matches its Crossref record.
Preliminary Findings: Behavioral Worsening on Donepezil in Patients With Frontotemporal Dementia
Abstract
Objective The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD). Methods Twelve patients with FTD who received donepezil for six months were compared with 12 FTD controls on behavioral measures. Results The groups did not differ on most variables at baseline or at six months; however, the donepezil group had greater worsening on the FTD Inventory. Four treated patients had increased disinhibited or compulsive acts, which abated with discontinuation of the medication. Conclusion There were no changes in global cognitive performance or dementia severity; however, a subgroup of patients with FTD can experience worsening of symptoms with donepezil.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, some bvFTD patients may experience behavioral or cognitive deterioration when exposed to these agents [37].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [37]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 9
- Neary, 1998, Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology, 51, 1546, 10.1212/WNL.51.6.1546 · DOI · Paper page
- Trinh, 2003, Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis, JAMA, 289, 210, 10.1001/jama.289.2.210 · DOI · Paper page
- Cummings, 2004, Reduction of behavioral disturbances and caregiver distress by galanthamine in patients with Alzheimer's disease, Am J Psychiatry, 161, 532, 10.1176/appi.ajp.161.3.532 · DOI
- Holmes, 2004, The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease, Neurology, 63, 214, 10.1212/01.WNL.0000129990.32253.7B · DOI
- Chow, 2002, Goals in symptomatic pharmacological management of frontotemporal dementia, Am J Alzheimers Dis Other Demen, 7, 267, 10.1177/153331750201700504 · DOI
- McMurtray, 2006, Variations in regional SPECT hypoperfusion and clinical features in frontotemporal dementia, Neurology, 66, 517, 10.1212/01.wnl.0000197983.39436.e7 · DOI
- Procter, 1999, Neurochemical features of frontotemporal dementia, Dement Geriatr Cogn Disord, 10, 80, 10.1159/000051219 · DOI
- Moretti, 2004, Rivastigmine in frontotemporal dementia: an open-label study, Drugs Aging, 21, 931, 10.2165/00002512-200421140-00003 · DOI
- Lampl, 2004, Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia, Ann Pharmacother, 38, 1967, 10.1345/aph.1D445 · DOI
Cited by
Sorted by citations
Items 201–224 of 224
Diagnosis and treatment for frontotemporal degenerations
Гришина, Д. А., Shpilyukova, Y. A., Борисовна, Л. А., & Fedotova, E. Y. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-19-42-50 · Cited by 1
Issues of diagnosis and treatment of frontotemporal degeneration
Гришина, Д. А. (2020) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-3-2020-217-224
Ong, K. T. (2018) · OBM Geriatrics · doi:10.21926/obm.geriatr.1803011
“One study found that in distinguishing between AD (n=62) and FTD (n=45) by visual reads, 11C-PiB had a sensitivity of 90% and a specificity of 83% where as FDG PET had a sensitivity of 78% and a specificity of 84%.”
BackgroundInfluentialTreatment of Late-Life Psychosis
Chima, V., Ndukwe, N., Maldonado, C. M., Sharma, P., & Lantz, M. (2018) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-018-0148-y
Ong, K., & Woodward, M. (2017) · Australian and New Zealand journal of psychiatry (Print) · doi:10.1177/0004867417694748
Frontotemporal dementia : caring for the caregiver
Seymour, S. C. (2016) · doi:10.15781/t2j960b6s
“For example, only Mioshi et al. (2013) and Roche et al. (2015) describe the FTD variants for which their participants cared. Both Riedijk et al. (2006) and Wong and Wallhagen (2012) state that caregivers in their studies were responsible for patients exhibiting behavioral problems.”
Franková, V., Matěj, R., & Rusina, R. (2015) · doi:10.14735/amcsnn2015209
The burden of epilepsy: data from an epilepsy clinic
Gamage, R., & Gooneratne, I. (2014) · Sri Lanka Journal of Neurology · doi:10.4038/sljon.v3i1.84
Role of antipsychotics for treating behavioral and psychological symptoms of dementia
Yap, K. Z. (2014) · World Journal of Pharmacology · doi:10.5497/wjp.v3.i4.174
Leitlinien zur „Pharmakotherapie neurodegenerativer Demenzen“
Fassbender, K., & Frölich, L. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4189-1
Varón de 67 años con pérdida de memoria y deterioro funcional
García, M. V., & Gregorio, P. (2014) · doi:10.1016/s0304-5412(14)70835-2
Frontotemporale Demenzen – Eine der häufigsten presenilen Demenzformen
Witt, K., & Deuschl, G. (2013) · Klinikarzt – Medizin im Krankenhaus · doi:10.1055/s-0033-1347103
Deterioro cognitivo vascular. Demencia por cuerpos de Lewy. Demencia frontotemporal. Otras demencias
Pascual, A., Palomo, M. S. M., & García, A. B. (2011) · doi:10.1016/s0304-5412(11)70070-1
Murden, R. (2011) · Journal of The American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03253.x
“Discovery of cerebrovascular disease in patients with suspected AD should prompt review for modifiable vascular risk factors, whereas treatment of frontotemporal dementia with cholinesterase inhibitors, although common,(2) is not well supported.(3) Optimizing dementia care in this fashion (and beyond) could shift trea…”
BackgroundBorghesani, P., & Borson, S. (2011) · doi:10.1111/j.1532-5415.2011.03270.x
“Discovery of cerebrovascular disease in patients with suspected AD should prompt review for modifiable vascular risk factors, whereas treatment of frontotemporal dementia with cholinesterase inhibitors, although common,(2) is not well supported.(3) Optimizing dementia care in this fashion (and beyond) could shift trea…”
BackgroundHu, W. T. L. (2010) · Continuum · doi:10.1212/01.con.0000368275.78318.3f
Scintigraphie cérébrale de perfusion et troubles cognitifs d’origine vasculaire
Farid, K., Ducasse, V., Meyer, L., Chokron, S., Peroz, J., Lieber, A., Helft, G., Blacher, J., & Caillat-Vigneron, N. (2010) · Médecine Nucléaire · doi:10.1016/j.mednuc.2010.05.009
Current awareness: Pharmacoepidemiology and drug safety
(2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1376
Anti-dementia Medications: Specific Agents
Zhang, F., Liu, X., Liu, Y., Wang, Y., & Le, W. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_283-1
Sawyer, R. P., Shinagawa, S., & Miller, B. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813866-3.00003-5 · Cited by 1
[Current approaches to the treatment of fronto-temporal dementia].
Fedorova, Y. (2019) · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · doi:10.17116/jnevro201911909218
Major or Mild Frontotemporal Neurocognitive Disorder
Hategan, A., Bourgeois, J. A., & Hirsch, C. H. (2017) · Springer eBooks · doi:10.1007/978-3-319-67555-8_19
Geriatric Anesthesia: Age-Dependent Changes in the Central and Peripheral Nervous Systems
Doshi, A. K., Cabeza, R. E. L., & Berger, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-66878-9_10 · Cited by 1
Shinagawa, S., & Miller, B. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00069-3 · Cited by 6
Metadata
- Authors
- Mendez, M. F., Shapira, J. S., McMurtray, A., & Licht, E.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Mendez, Mario F.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 15
- Issue
- 1
- Pages
- 84-87
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W2058247742
- Cited by
- 267
- References
- 0
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 9 · 2023: 13 · 2022: 11 · 2021: 23 · 2020: 14 · 2019: 19 · 2018: 13 · 2017: 16 · 2016: 19 · 2015: 6 · 2014: 19 · 2013: 18 · 2012: 11
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG19724-01, P01AG019724)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donepezil, frontotemporal dementia, acetylcholinesterase inhibitors, behavioral disinhibition, compulsive behavior, adverse drug reactions, cognitive performance
- MeSH terms
- Donepezil, Behavioral Symptoms, Cholinesterase Inhibitors, Compulsive Behavior, Dementia, Female, Humans, Indans, Male, Middle Aged, Piperidines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
